Anvisa Approves Semaglutide-Based Ylumec Pen for Type 2 Diabetes
5 Articles
5 Articles
semaglutida, ozempic Freepik The National Agency for Health Surveillance (Anvisa) approved the registration of a new EMS EMS medicine semimaglutide pen. The medicine, called Yluméc, will be a new option for the treatment of type 2 diabetes in the country. Yluméc contains semaglutide, the same active principle of medicines such as Ozempic and Wegovy, from Novo Nordisk, and Ozivy, also from EMS. Despite using the same substance, the new medicine i…
EMS medicine uses the same active principle as Ozempic and Wegovy; there are no sales forecasts or price definitions yet The post Anvisa approves new Semaglutide pen for type 2 diabetes; see how it works appeared first on GMC Online.
Yluméc has been registered as a similar medicine and will have versions in application pens; product is for weekly use
Metrópoles
gazetaweb.comEMS medicine uses the same active principle as Ozempic and Wegovy; no sales forecast or price definition yet
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
